The importance of early veno-arterial extracorporeal membrane oxygenation in the management of amniotic fluid embolism complicated by cardiac arrest: a case report and literature review Authors: Junyou Su, Jing Luo, Hongfei Chen, Junru Tong, Yan Chen, Lingling Huang, Xiaoting Huang, Shi Liao, Yan Huang, Li Deng Published: 2025 ABSTRACT BackgroundAmniotic fluid embolism (AFE) with cardiac arrest is an obstetric emergency with an exceedingly high maternal mortality. Early application of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) may provide essential cardiopulmonary support, but its clinical value warrants further investigation.Case reportThis report describes the successful management of a 36-year-old parturient with advanced maternal age who sustained sudden cardiac arrest due to AFE during the second stage of labor. Immediately following arrest, the patient received high-quality CPR and achieved return of spontaneous circulation (ROSC) within four minutes. A multidisciplinary team initiated early VA-ECMO support with an anticoagulation-free strategy post-ROSC, acting as a critical bridging therapy to cardiopulmonary recovery. Although total hysterectomy was subsequently performed for refractory severe postpartum hemorrhage, the patient ultimately achieved complete recovery and was discharged without sequelae, including thromboembolic complications or severe neurological deficits.ConclusionsThis case demonstrates the feasibility and potential utility of early VA-ECMO as a resuscitative therapy for AFE-induced cardiac arrest. Its successful application in this setting justifies further evaluation of ECPR in peripartum emergencies. Introduction Amniotic fluid embolism (AFE) is a rare yet life-threatening intrapartum complication, with an estimated incidence of 2–8 cases per 100,000 pregnancies and a case fatality rate as high as 86% [1, 2]. The classic clinical phenotype of AFE involves the sudden onset of hypoxemia, hypotension, and coagulopathy, which can rapidly progress to cardiac arrest and fatal outcomes in severe cases [3, 4]. Immediate initiation of high-quality cardiopulmonary resuscitation (CPR) following cardiac arrest is critical for salvaging both maternal and fetal lives; however, the enlarged gravid uterus may partially compromise the efficacy of resuscitative efforts [5]. Furthermore, during the post-resuscitation phase, pulmonary hypertension secondary to pulmonary vascular obstruction and vasospasm, combined with myocardial depression triggered by a systemic inflammatory storm, frequently results in the inability to maintain effective cardiopulmonary circulation [6, 7]. Consequently, for AFE patients complicated by cardiac arrest, there is an urgent need for an advanced life support modality capable of simultaneously replacing cardiopulmonary function and affording a window for organ recovery.​ Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) can partially or completely substitute for cardiac and pulmonary function, rapidly improving oxygenation, reducing pulmonary artery pressure, and alleviating cardiac afterload. Currently, it is increasingly utilized in the resuscitation of patients with refractory cardiac arrest [8, 9]. Although isolated case reports have described the application of VA-ECMO in AFE management, it has often been limited to salvage intervention in the late phase of resuscitation. This article presents a case of successful management of an AFE patient via early VA-ECMO initiation following cardiac arrest. Combined with a literature review, we aim to explore the significance of early VA-ECMO application in the treatment of AFE with concurrent cardiac arrest, with the goal of providing a clinical reference for managing similar cases. Case report A 36-year-old woman, gravida 5 para 2, at 38+ 5 weeks of gestation, was admitted for labor surveillance due to abdominal pain concerning for impending labor. Prenatal evaluations were unremarkable, her medical history was non-contributory, and admission physical examination and adjunctive investigations were within normal limits. After experiencing premature rupture of membranes on the second day of hospitalization, the patient went into labor with regular uterine contractions starting at 07:00. Due to intractable labor pain, epidural anesthesia for labor analgesia was administered at 09:15. At 11:00, with complete cervical dilation, the patient entered the second stage of labor and was instructed on pushing techniques while on the delivery bed. She received supplemental oxygen via nasal cannula, continuous electrocardiographic monitoring, and fetal heart rate (FHR) monitoring. At 11:10, the patient experienced sudden loss of consciousness, became unresponsive, and exhibited apnea and pulselessness. Cardiac monitoring demonstrated asystole, while oxygen saturation and blood pressure were unmeasurable. FHR monitoring revealed severe bradycardia (40–50 beats/min). A diagnosis of AFE complicated by cardiac arrest and fetal distress was highly suspected. CPR was immediately initiated, including continuous manual chest compressions at a depth of 5–6 cm and a rate of 100–120 per minute, endotracheal intubation with mechanical ventilation, left uterine displacement (LUD), and intravenous administration of 1 mg adrenaline every 3–5 min. A multidisciplinary team (MDT), comprising specialists from Obstetrics, Critical Care Medicine, Neonatology, Anesthesiology, Blood Transfusion Services, and Laboratory Medicine, was rapidly convened. Given complete cervical dilation and fetal head at station + 2, an emergent forceps-assisted vaginal delivery was performed. At 11:15, a live male neonate was delivered, with Apgar scores of 6, 8, and 9 at 1, 5, and 10 min, respectively. Following the return of spontaneous circulation (ROSC), milrinone and dobutamine were administered for hemodynamic support, papaverine for pulmonary vasodilation, and hydrocortisone for potential anti-allergic effects. At 11:19, the patient achieved return of spontaneous circulation (ROSC); however, her blood pressure was 78/52 mmHg. Arterial blood gas (ABG) analysis showed: pH 7.232, PaO₂ 20.10 mmHg, PaCO₂ 48.20 mmHg, Base Excess (BE) −7.30 mmol/L, Lactate (Lac) 5.4 mmol/L. Following MDT deliberation, and given the patient’s refractory hypotension despite catecholamine support, profound hypoxemia, and worsening lactic acidosis after ROSC, a decision was made to urgently initiate VA-ECMO without systemic anticoagulation. Following the mobilization of the VA-ECMO circuit from the intensive care unit, percutaneous cannulation was performed by intensivists. The procedure was conducted using the Seldinger technique under ultrasound guidance, with a 17 Fr cannula inserted into the right femoral artery and a 21 Fr cannula into the right femoral vein. A distal perfusion catheter (7 Fr) was subsequently placed in the superficial femoral artery to prevent critical limb ischemia. The entire procedure was performed at the bedside in the delivery room to avoid the risks associated with transferring an unstable patient. During cannulation, the placenta and fetal membranes were completely delivered at 11:20, followed by active vaginal bleeding with non-clotting blood. Coagulation profiles revealed severe hypofibrinogenemia (FIB 0.68 g/L) and markedly prolonged Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT), consistent with disseminated intravascular coagulation (DIC). A massive transfusion protocol (MTP) was immediately activated, with targeted transfusion of leukoreduced packed red blood cells, fresh frozen plasma, platelet concentrates, and fibrinogen to correct coagulopathy. Concurrent interventions included fluid resuscitation for hypovolemic shock, sodium bicarbonate for metabolic acidosis correction, carboprost tromethamine and oxytocin for uterine atony, and tranexamic acid for hemorrhage control. By 11:39, estimated blood loss was 900 mL. To manage postpartum hemorrhage, an intrauterine balloon tamponade was placed. Although the bleeding rate diminished post-tamponade, persistent oozing persisted. By 12:12, VA-ECMO was successfully established and initiated with the following settings: pump speed 3900 rpm, oxygen flow 2.0 L/min, blood flow 3.90 L/min, fraction of inspired oxygen (FiO2) 100%. Following VA-ECMO initiation, the patient’s vital signs gradually stabilized. With the patient on mechanical ventilation (FiO₂ 50%), serial ABG analysis showed: pH 7.015, PaO₂ 108.00 mmHg, PaCO₂ 54.7 mmHg, BE −17.10 mmol/L, Lac 13.0 mmol/L. However, active vaginal bleeding persisted, with cumulative blood loss reaching 2500 mL by 14:00. To preserve the patient’s life, a total hysterectomy was performed. Total blood loss from delivery to the conclusion of surgery was 7200 mL. Transfused components included 30 units of packed red blood cells, 3 therapeutic doses of platelets, 4740 mL of fresh frozen plasma, 51.5 units of cryoprecipitate, 100 g of human albumin, and 16 g of fibrinogen concentrate. Postoperative monitoring revealed: blood pressure (BP) 125/95 mmHg, oxygen saturation (SpO₂) 95%, heart rate (HR) 129 bpm. The patient was transferred to the Intensive Care Unit (ICU) for further management.​ In the ICU, the patient received advanced life support, including VA-ECMO support, coagulopathy and anemia correction, infection prophylaxis, hemodynamic optimization, and neuroprotective therapy (such as targeted temperature management (TTM), strict avoidance of hyperglycemia and hyperoxia, and neuroprotective drugs, etc.). Transthoracic echocardiography on the day of surgery showed a pulmonary artery systolic pressure of 20 mmHg, left ventricular ejection fraction (EF) of 54%, and resting interventricular septal hypokinesis. A chest CT scan performed on postoperative day 1 revealed bilateral pulmonary opacities, compatible with pneumonia and/or pulmonary edema, along with bilateral pleural effusions and associated compressive atelectasis of the lower lobes. By postoperative day 3, her vital signs were stable. An ABG analysis obtained under mechanical ventilation (FiO₂ 40%) and VA-ECMO support (sweep gas FiO₂ 45%) indicated: pH 7.445, PaO₂ 172.00 mmHg, PaCO₂ 39.1 mmHg, BE 2.6 mmol/L, Lac 1.7 mmol/L. VA-ECMO was successfully weaned on postoperative day 3. Discontinuation of VA-ECMO was based on the fulfillment of the following criteria: hemodynamic stability (MAP > 65 mmHg with minimal norepinephrine), echocardiographic recovery of LVEF to ≥ 50%, a PaO₂/FiO₂ ratio > 200 on ≤ 40% FiO₂, lactate normalization below 2.0 mmol/L, and sustained stability during a low-flow ECMO trial. Post-decannulation, her heart rate ranged from 90 to 100 bpm, blood pressure from 110–135/60–70 mmHg, pulse oximetry was 100%, and respiratory rate was 16–18 breaths/min. On postoperative day 5, mechanical ventilation was discontinued, and the endotracheal tube was extubated. Following clinical stabilization, she was transferred back to the general obstetric ward on postoperative day 7. Due to symptoms of tongue protrusion difficulty and dysarthria, a brain magnetic resonance imaging (MRI) scan performed on January 24 revealed a small right subtentorial subdural hematoma (subacute phase), measuring approximately 2.4 cm × 0.9 cm. With neurotrophic therapy, these symptoms gradually improved.​ The patient was discharged on postoperative day 18. Pre-discharge investigations confirmed resolution of coagulopathy and anemia (Table 1). Endocrine testing for cortisol and adrenocorticotropic hormone (ACTH) showed no evidence of Sheehan’s syndrome. Duplex Doppler ultrasound of both lower extremities revealed no femoral artery injury or venous thrombosis. Uterine pathological examination demonstrated marked myometrial edema, congestion, and thickening, consistent with AFE accompanied by hyaline thrombi (Fig. 1). At the six-month follow-up, both the mother and neonate showed favorable outcomes: the mother had achieved full recovery without significant sequelae, and the neonate exhibited normal growth and development. Final Diagnoses: (1) Amniotic Fluid Embolism; (2) Cardiac Arrest (post-resuscitation); (3) Hypoxic-Ischemic Encephalopathy; (4) Disseminated Intravascular Coagulation; (5) Severe Postpartum Hemorrhage; (6) Fetal Distress; (7) Status Post Total Hysterectomy; (8) Gravida 5 Para 3, Term Forceps-Assisted Vaginal Delivery at 39 Weeks’ Gestation. Table 1The main changes in the patient’s laboratory resultsParameterAdmissionPre-VA-ECMO InitiationPost-VA-ECMO InitiationDuring Hysterectomy(Post-VA-ECMO)ICU TransferPost-op Day 1Post-op Day 2Post-op Day 3Pre-DischargeNormal valuesWBC (×10⁹/L)13.5318.9821.3612.349.658.0711.5711.375.953.50–9.50Hb (g/L)110.00112.0060.0067.0069.0072.0078.0082.00114.00115.00–150.00.00.00PLT (×10⁹/L)237.00179.00185.0082.0057.0056.0032.0042.00600.00125.00–350.00.00.00FIB (g/L)5.060.680.710.922.432.873.413.162.762.38–4.98PT (s)10.9019.2018.8015.7013.0012.5012.8011.7012.309.40–12.50PTA (%)102.0044.0045.0057.0076.0081.0078.0090.0083.0070.00–130.00.00.00APTT (s)29.6072.70132.1075.1041.9033.20137.6032.6031.5025.10–36.50DD (mg/L)-163160.0060273.0061008.006117.002140.001615.002672.001631.000.00–243.00.00.00CK (U/L)-330.00318.00322.00562.00-323.00-92.0026.00–192.00.00.00LD (U/L)-792.00675.00225.00256.00-261.00-431.00120.00–250.00.00.00TB (µmol/L)6.208.9011.1035.4056.8046.4027.2017.9013.100.00–21.00ALT (U/L)13.0039.0026.0015.0017.0018.0021.0027.0045.007.00–40.00Serum CREA (µmol/L)41.0073.0083.0079.0084.00-72.00-63.0041.00–73.00PCT (ng/mL)----47.9047.1035.9018.500.1850.00–0.05.00.05ABG - pH-7.2327.0157.3587.5317.4737.5477.4457.4187.35–7.45pO₂ (mmHg)20.10108.0096.40100.00119.00136.00172.00138.0083.00–108.00.00.00 (on room air)pCO₂ (mmHg)48.2054.7047.1026.5036.9030.7039.1028.3035.00–45.00 (on room air)Lac (mmol/L)5.4013.1010.609.105.902.201.72.000.50–1.60WBC White Blood Cells, Hb Hemoglobin, PLT Platelets, FIB Fibrinogen, PT Prothrombin Time, PTA Prothrombin Time Activity, APTT Activated Partial Thromboplastin Time, DD D-dimer, CK Creatine Kinase, LD Lactate Dehydrogenase, TB Total Bilirubin, ALT Alanine Aminotransferase, CREA Creatinine, PCT Procalcitonin, ABG Arterial Blood Gas, Lac Lactate Table 1The main changes in the patient’s laboratory resultsParameterAdmissionPre-VA-ECMO InitiationPost-VA-ECMO InitiationDuring Hysterectomy(Post-VA-ECMO)ICU TransferPost-op Day 1Post-op Day 2Post-op Day 3Pre-DischargeNormal valuesWBC (×10⁹/L)13.5318.9821.3612.349.658.0711.5711.375.953.50–9.50Hb (g/L)110.00112.0060.0067.0069.0072.0078.0082.00114.00115.00–150.00.00.00PLT (×10⁹/L)237.00179.00185.0082.0057.0056.0032.0042.00600.00125.00–350.00.00.00FIB (g/L)5.060.680.710.922.432.873.413.162.762.38–4.98PT (s)10.9019.2018.8015.7013.0012.5012.8011.7012.309.40–12.50PTA (%)102.0044.0045.0057.0076.0081.0078.0090.0083.0070.00–130.00.00.00APTT (s)29.6072.70132.1075.1041.9033.20137.6032.6031.5025.10–36.50DD (mg/L)-163160.0060273.0061008.006117.002140.001615.002672.001631.000.00–243.00.00.00CK (U/L)-330.00318.00322.00562.00-323.00-92.0026.00–192.00.00.00LD (U/L)-792.00675.00225.00256.00-261.00-431.00120.00–250.00.00.00TB (µmol/L)6.208.9011.1035.4056.8046.4027.2017.9013.100.00–21.00ALT (U/L)13.0039.0026.0015.0017.0018.0021.0027.0045.007.00–40.00Serum CREA (µmol/L)41.0073.0083.0079.0084.00-72.00-63.0041.00–73.00PCT (ng/mL)----47.9047.1035.9018.500.1850.00–0.05.00.05ABG - pH-7.2327.0157.3587.5317.4737.5477.4457.4187.35–7.45pO₂ (mmHg)20.10108.0096.40100.00119.00136.00172.00138.0083.00–108.00.00.00 (on room air)pCO₂ (mmHg)48.2054.7047.1026.5036.9030.7039.1028.3035.00–45.00 (on room air)Lac (mmol/L)5.4013.1010.609.105.902.201.72.000.50–1.60WBC White Blood Cells, Hb Hemoglobin, PLT Platelets, FIB Fibrinogen, PT Prothrombin Time, PTA Prothrombin Time Activity, APTT Activated Partial Thromboplastin Time, DD D-dimer, CK Creatine Kinase, LD Lactate Dehydrogenase, TB Total Bilirubin, ALT Alanine Aminotransferase, CREA Creatinine, PCT Procalcitonin, ABG Arterial Blood Gas, Lac Lactate The main changes in the patient’s laboratory results WBC White Blood Cells, Hb Hemoglobin, PLT Platelets, FIB Fibrinogen, PT Prothrombin Time, PTA Prothrombin Time Activity, APTT Activated Partial Thromboplastin Time, DD D-dimer, CK Creatine Kinase, LD Lactate Dehydrogenase, TB Total Bilirubin, ALT Alanine Aminotransferase, CREA Creatinine, PCT Procalcitonin, ABG Arterial Blood Gas, Lac Lactate Fig. 1Pathological examination of the uterus. Amniotic fluid components and keratin squames are identified within the blood vessels of the lower uterine segment, with hyaline thrombi observed in multiple small vessels. (H&E staining, original magnification ×400) Pathological examination of the uterus. Amniotic fluid components and keratin squames are identified within the blood vessels of the lower uterine segment, with hyaline thrombi observed in multiple small vessels. (H&E staining, original magnification ×400) Discussion AFE is a rare and life-threatening obstetric complication characterized by sudden onset, rapid progression, and unpredictability. Its exact pathogenesis remains incompletely delineated. Current evidence suggests that the entry of amniotic fluid components into the maternal systemic circulation induces mechanical obstruction and triggers a systemic inflammatory response syndrome, subsequently leading to pulmonary hypertension, cardiorespiratory failure, cardiac arrest, and disseminated intravascular coagulation (DIC) [4, 10, 11]. Established risk factors for AFE include advanced maternal age, inappropriate oxytocin administration, placenta previa or placental abruption, and multiple gestation [12, 13]. In this case, the patient was 36 years old (consistent with advanced maternal age) and had a history of multiple pregnancies and abortions. Anticipating the elevated risk of postpartum hemorrhage and AFE associated with these factors, dual intravenous access was established during labor— a measure that proved critical for timely drug administration during cardiac arrest resuscitation​. The cornerstone of AFE management is early recognition and prompt intervention. Diagnosis is primarily based on clinical manifestations, with hallmark symptoms including sudden cardiorespiratory dysfunction (e.g., hypoxemia, hypotension, cardiac arrest) and coagulopathy occurring during labor or the immediate postpartum period [2, 4]. Therefore, AFE should be included in the differential diagnosis of any peripartum cardiac arrest. In this case, cardiac arrest occurred acutely during the second stage of labor. While high-quality CPR was initiated, medications including pulmonary vasodilators and corticosteroids were administered in accordance with AFE management guidelines. However, during the post-resuscitation phase, the patient developed cardiopulmonary insufficiency secondary to heart failure, pulmonary edema, and persistent pulmonary hypertension. Notably, approximately 89% of AFE-related deaths are associated with cardiac arrest [14], highlighting the limitations of conventional therapies in restoring and maintaining effective cardiopulmonary function.​ In recent years, extracorporeal membrane oxygenation (ECMO) has emerged as a promising therapeutic modality for AFE complicated by cardiac arrest. ECMO is an extracorporeal life support technique designed for patients with refractory cardiac and/or respiratory failure, primarily including the veno-venous (VV) mode (for isolated respiratory support) and the veno-arterial (VA) mode (for combined cardiorespiratory support). However, ECMO application in AFE presents unique challenges: AFE is frequently complicated by hyperfibrinolysis and DIC, which increase bleeding risk—while active bleeding or severe coagulopathy are relative contraindications for ECMO, posing challenges for anticoagulation management. Additionally, complications such as hemorrhage and thromboembolism remain major concerns and points of contention in ECMO use for AFE, potentially limiting its early implementation. Despite these challenges, accumulating evidence supports favorable outcomes with ECMO in obstetric patients. A multicenter retrospective study by Malfertheiner et al. [15] reported maternal and fetal survival rates of 87% and 73%, respectively, among patients receiving ECMO during pregnancy. A systematic summary of ECMO use during pregnancy and the peripartum period (1972–2017) by Ong et al. [16] documented maternal and fetal survival rates of 91% and 78%, respectively. Furthermore, Buda et al. [17] analyzed 31 AFE patients treated with VA-ECMO between 2016 and 2021, reporting a survival rate of 62%. Growing evidence indicates that ECMO can improve maternal and fetal survival in cases of refractory cardiorespiratory failure [6]. Thus, ECMO application holds significant clinical relevance in AFE patients complicated by cardiac arrest.​ In this case, VA-ECMO support without systemic anticoagulation was initiated immediately following successful CPR. However, the interval from decision-making to cannulation and ECMO flow initiation was 53 minutes, with challenges in femoral artery cannulation attributed to poor vascular filling secondary to AFE-induced pulmonary hypertension and heart failure—a common obstacle in ECMO establishment for patients with circulatory collapse. Furthermore, the complex coordination required to rapidly mobilize a specialized ECMO team and equipment to the obstetric unit—a non-traditional setting for this intervention. In cases of AFE with post-ROSC refractory cardiopulmonary failure, early ECMO consideration may be critical. This timeframe underscores that ‘early’ application depends not only on clinical decision-making but also on institutional resources and the complex logistics of mobilizing specialized teams to non-ICU settings. With VA-ECMO support, this AFE patient with cardiac arrest achieved successful outcomes, without thromboembolic events, significant end-organ damage, or irreversible neurological deficits. Although brain MRI revealed a small subdural hematoma, this was attributed to underlying DIC rather than ECMO-related complications. The transient rise in procalcitonin was attributed to the systemic inflammatory response triggered by the amniotic fluid embolism and subsequent major surgery. Its subsequent decline supported the absence of a significant secondary bacterial infection. Overall, VA-ECMO effectively provided temporary cardiopulmonary replacement, facilitated a window for organ recovery, maintained systemic perfusion, corrected lactic acidosis, and ensured adequate tissue oxygenation. Early VA-ECMO initiation was a key determinant of the patient’s survival and absence of severe complications. Additionally, due to AFE-induced DIC and thrombocytopenia, an anticoagulation-free strategy was implemented, and ECMO was promptly weaned upon cardiac function improvement—measures that minimized ECMO-related complications. Concurrently, early recognition of AFE risk factors and rapid MDT mobilization for collaborative management were also critical to the successful outcome.​ In conclusion, this case suggests that early VA-ECMO may have therapeutic value in managing cardiac arrest due to AFE and that this approach deserves further exploration as a treatment strategy for this rare obstetric emergency. However, its application remains limited by resource constraints, technical demands, and the absence of robust clinical evidence. Given this postpartum complication’s rarity and ECMO’s resource/financial demands, large-sample rigorous studies are inherently unfeasible. Future research could focus on multi-center real-world data, small-sample prospective cohorts, or case-series pooled analysis to further validate early ECMO’s efficacy and safety.